Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Avila-Nieto, Carlos
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Rodon, Jordi|||0000-0002-1032-9091
  • Urrea, Víctor|||0000-0002-2577-856X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Blanco, Julià|||0000-0002-2225-0217
  • Guallar, Victor|||0000-0002-4580-1114
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development. In this study, the authors report a mutation that increases the production of recombinant SARS-CoV-2 Spike and exposure of the RBD. In animal models, a Spike-based vaccine containing the mutation induces strong immunogenicity, provides protection from disease and results in faster tissue viral clearance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Amengual-Rigo, Pep
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Gracia Carmona, Oriol
  • Urrea, Víctor|||0000-0002-2577-856X
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Blanco-Heredia, Juan|||0000-0001-9526-7450
  • Anjos-Souza, Carla|||0000-0003-0671-7275
  • Varela, Ismael|||0000-0002-3825-372X
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Lepore, Rosalba
  • Vázquez, Miguel
  • De Mattos-Arruda, Leticia|||0000-0002-4992-3645
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Guallar, Victor|||0000-0002-4580-1114
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
Background: Neoantigens are patient- and tumor-specific peptides that arise from somatic mutations. They stand as promising targets for personalized therapeutic cancer vaccines. The identification process for neoantigens has evolved with the use of next-generation sequencing technologies and bioinformatic tools in tumor genomics. However, in-silico strategies for selecting immunogenic neoantigens still have very low accuracy rates, since they mainly focus on predicting peptide binding to Major Histocompatibility Complex (MHC) molecules, which is key but not the sole determinant for immunogenicity. Moreover, the therapeutic potential of neoantigen-based vaccines may be enhanced using an optimal delivery platform that elicits robust de novo immune responses. Methods: We developed a novel neoantigen selection pipeline based on existing software combined with a novel prediction method, the Neoantigen Optimization Algorithm (NOAH), which takes into account structural features of the peptide/MHC-I interaction, as well as the interaction between the peptide/MHC-I complex and the TCR, in its prediction strategy. Moreover, to maximize neoantigens' therapeutic potential, neoantigen-based vaccines should be manufactured in an optimal delivery platform that elicits robust de novo immune responses and bypasses central and peripheral tolerance. Results: We generated a highly immunogenic vaccine platform based on engineered HIV-1 Gag-based Virus-Like Particles (VLPs) expressing a high copy number of each in silico selected neoantigen. We tested different neoantigen-loaded VLPs (neoVLPs) in a B16-F10 melanoma mouse model to evaluate their capability to generate new immunogenic specificities. NeoVLPs were used in in vivo immunogenicity and tumor challenge experiments. Conclusions: Our results indicate the relevance of incorporating other immunogenic determinants beyond the binding of neoantigens to MHC-I. Thus, neoVLPs loaded with neoantigens enhancing the interaction with the TCR can promote the generation of de novo antitumor-specific immune responses, resulting in a delay in tumor growth. Vaccination with the neoVLP platform is a robust alternative to current therapeutic vaccine approaches and a promising candidate for future personalized immunotherapy.